A5066628879- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- Synthesis and Biological Evaluation
- Radiopharmaceutical Chemistry and Applications
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- PARP inhibition in cancer therapy
- Lymphoma Diagnosis and Treatment
- Signaling Pathways in Disease
- Lung Cancer Diagnosis and Treatment
- Virus-based gene therapy research
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Chemokine receptors and signaling
- Radiation Dose and Imaging
- Toxin Mechanisms and Immunotoxins
- DNA Repair Mechanisms
- Integrated Circuits and Semiconductor Failure Analysis
- Pancreatic function and diabetes
- Cardiac Imaging and Diagnostics
University of Pennsylvania
2015-2025
Hospital of the University of Pennsylvania
2014-2024
California University of Pennsylvania
2021-2024
Duke University
2023
University of Alabama at Birmingham
2023
Siemens (Germany)
2022
Merck (Germany)
2022
Bayer (Germany)
2022
Weatherford College
2022
Penn Center for AIDS Research
2021-2022
Immunotherapy is becoming the mainstay for treatment of a variety malignancies, but only subset patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T lymphocytes play central role in antitumor immune responses. Noninvasive imaging CD8+ cells may provide new insights into mechanisms immunotherapy and potentially predict response. We are studying safety utility <sup>89</sup>Zr-IAB22M2C, radiolabeled minibody against cells, targeted with cancer. <b>Methods:</b> The initial...
BACKGROUND. Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in a broad population of patients with ovarian cancer; however, resistance caused by low enzyme expression the drug target PARP-1 remains to be clinically evaluated this context. We hypothesize that is variable cancer and can quantified primary metastatic disease using novel PET imaging agent.
There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor infiltrating CD8+ leukocytes. Such could be used to predict early response cancer immunotherapy, help select effective single or combination immunotherapies, and facilitate the development of new immunotherapies immunotherapy combinations. This study was designed optimize conditions performing CD8 PET with <sup>89</sup>Zr-Df-IAB22M2C determine if provide safe non-invasive method visualizing whole body...
We conducted a phase I trial evaluating pembrolizumab+hypofractionated radiotherapy (HFRT) for patients with metastatic cancers.There were two strata (12 each): (i) NSCLC/melanoma progressing on prior anti-PD-1 therapy, (ii) other cancer types; anti-PD-1-naive. Patients received 6 cycles of pembrolizumab, starting 1 week before HFRT. had ≥2 lesions; only one was irradiated (8 Gy × 3 first half; 17 second half in each stratum) and the other(s) followed response.Of 24 patients, 20 (83%)...
Cell-based therapeutics have considerable promise across diverse medical specialties; however, reliable human imaging of the distribution and trafficking genetically engineered cells remains a challenge. We developed positron emission tomography (PET) probes based on small-molecule antibiotic trimethoprim (TMP) that can be used to image expression Escherichia coli dihydrofolate reductase enzyme (eDHFR) tested ability [18F]-TMP, fluorine-18 probe, primary chimeric antigen receptor (CAR) T...
Despite the success of chimeric antigen receptor (CAR) T-cell therapy against hematologic malignancies, successful targeting solid tumors with CAR T cells has been limited by a lack durable responses and reports toxicities. Our understanding therapeutic efficacy in could be improved quantitative tools that allow characterization T-targeted antigens accurate monitoring response.
Abstract Immune checkpoint inhibitors (ICI) have been effective in treating a subset of refractory solid tumors, but only small percentage treated patients benefit from these therapies. Thus, there is clinical need for reliable tools that allow the early assessment response to ICIs, as well preclinical imaging aid future development and understanding immunotherapies. Here we demonstrate CD69, canonical early-activation marker expressed on variety activated immune cells, including cytotoxic T...
Abstract Purpose: Immunologic response to anti–programmed cell death protein 1 (PD-1) therapy can occur rapidly with T-cell responses detectable in as little one week. Given that activated immune cells are FDG avid, we hypothesized an early PET/CT obtained approximately week after starting pembrolizumab could be used visualize a metabolic flare (MF), increased tumor activity due infiltration by cells, or (MR), death, would predict response. Patients and Methods: Nineteen patients advanced...
This nonrandomized clinical trial tested [18F]FluorThanatrace as a method for measuring regional poly–(adenosine diphosphate–ribose) polymerase 1 expression in breast cancer and potential functional biomarker inhibitor response.
Fluorine-18 fluorodeoxyglucose (FDG) with positron emission tomography (PET) is the standard for detecting myocardial inflammation in cardiac sarcoidosis, requiring preparation ketogenic diet (KD) to achieve glucose suppression. Despite this, incomplete suppression remains a significant issue, and strategies reduce uptake (MGU) identify are required. This study sought understand relationship between point-of-care beta-hydroxybutyrate (BHB) different patterns of MGU KD fasting duration...
Monoclonal antibodies are highly specific for their targets making them effective cancer therapy. However, large molecular weight causes slow blood clearance, often requiring weeks to be removed from circulation. This limitation affects companion nuclear imaging and antibody-based diagnostics, necessitating delayed imaging. We report the expansion of a methodology improving positron emission tomography (PET) contrast lymphoma biomarker CD20 at early time points after radiolabeled antibody...
Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for Breast Cancer gene (BRCA)-mutant HER2- breast cancer, and there is clinical interest in expanding indications to include homologous recombination deficient (HRD) cancers. Yet, response these populations remains variable, suggesting utility developing a better biomarker select patients PARPi predict response. Here, we evaluate radiolabeled PARPi, [18F]FluorThanatrace ([18F]FTT), as functional of cancer. A single-arm prospective...